Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 4, 45
eCollection

Selective Serotonin Reuptake Inhibitor Antidepressant Treatment Discontinuation Syndrome: A Review of the Clinical Evidence and the Possible Mechanisms Involved

Affiliations

Selective Serotonin Reuptake Inhibitor Antidepressant Treatment Discontinuation Syndrome: A Review of the Clinical Evidence and the Possible Mechanisms Involved

Thibault Renoir. Front Pharmacol.

Abstract

Besides demonstrated efficacy, selective serotonin reuptake inhibitors (SSRIs) hold other advantages over earlier antidepressants such as greater tolerability and a wider range of clinical applications. However, there is a growing body of clinical evidence which suggests that SSRIs could, in some cases, be associated with a withdrawal reaction upon cessation of regular use. In addition to sensory and gastrointestinal-related symptoms, the somatic symptoms of the SSRI discontinuation syndrome include dizziness, lethargy, and sleep disturbances. Psychological symptoms have also been documented, usually developing within 1-7 days following SSRI discontinuation. The characteristics of the discontinuation syndrome have been linked to the half-life of a given SSRI, with a greater number of reports emerging from paroxetine compared to other SSRIs. However, many aspects of the neurobiology of the SSRI discontinuation syndrome (or SSRI withdrawal syndrome) remain unresolved. Following a comprehensive overview of the clinical evidence, we will discuss the underlying pathophysiology of the SSRI discontinuation syndrome and comment on the use of animal models to better understand this condition.

Keywords: SSRI discontinuation syndrome; SSRI withdrawal syndrome; animal models; antidepressant treatment; clinical evidence; selective serotonin reuptake inhibitor; serotonin.

Similar articles

See all similar articles

Cited by 11 PubMed Central articles

See all "Cited by" articles

References

    1. Anthony J. P., Sexton T. J., Neumaier J. F. (2000). Antidepressant-induced regulation of 5-HT(1b) mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation. J. Neurosci. Res. 61, 82–8710.1002/1097-4547(20000701)61:1<82::AID-JNR10>3.0.CO;2-E - DOI - PubMed
    1. Baldwin D. S., Montgomery S. A., Nil R., Lader M. (2007). Discontinuation symptoms in depression and anxiety disorders. Int. J. Neuropsychopharmacol. 10, 73–8410.1017/S1461145705006358 - DOI - PubMed
    1. Barbon A., Orlandi C., La Via L., Caracciolo L., Tardito D., Musazzi L., et al. (2011). Antidepressant treatments change 5-HT2C receptor mRNA expression in rat prefrontal/frontal cortex and hippocampus. Neuropsychobiology 63, 160–16810.1159/000321593 - DOI - PubMed
    1. Benmansour S., Cecchi M., Morilak D. A., Gerhardt G. A., Javors M. A., Gould G. G., et al. (1999). Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J. Neurosci. 19, 10494–10501 - PMC - PubMed
    1. Benmansour S., Owens W. A., Cecchi M., Morilak D. A., Frazer A. (2002). Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J. Neurosci. 22, 6766–6772 - PMC - PubMed

LinkOut - more resources

Feedback